CTLA4 and neoplasm: (76) once experimentally confirmed that B cells can modulate the anti-tumor immune response by mediating proliferation and functional polarization of T cells, and they also found that a potential law in patients receiving CTLA-4 inhibitors where a lack of B cell response is possibly a sign of poor response to ICIs.